论文部分内容阅读
目的:探讨左炔诺孕酮宫内缓释系统(LNG-IUS,商品名:曼月乐)在治疗子宫腺肌病中的临床疗效及安全性。方法:将笔者所在医院妇科就诊有治疗意愿的子宫腺肌病伴中度或重度痛经及月经过多的患者48例,放置曼月乐进行治疗,观察曼月乐治疗前、治疗后3个月、6个月、12个月的痛经程度、月经量、血红蛋白、血清CA125水平、子宫体积变化、子宫内膜厚度变化等情况。结果:曼月乐治疗后3个月患者痛经明显缓解,月经量明显减少,子宫内膜厚度变薄,与放置前相比较,差异均有统计学意义(P<0.05);10例贫血患者放置(LNG-IUS)3个月、6个月、12个月后血红蛋白升高,与放置前相比较差异有统计学意义(P<0.05);血清CA125在放置后12个月明显下降,与放置前比较差异有统计学意义(P<0.05)。子宫体积稍有缩小,但与放置前相比较差异均无统计学意义(P>0.05)。不良反应主要表现有4例阴道点滴出血、3例闭经、1例乳房胀痛、1例环脱落,其他未见不良反应。结论:曼月乐对子宫腺肌病的治疗安全有效,有较好的临床应用价值。
Objective: To investigate the clinical efficacy and safety of levonorgestrel-releasing intrauterine system (LNG-IUS, trade name: Mirena) in the treatment of adenomyosis. Methods: The author where the hospital gynecological treatment of patients with adenomyosis with or without moderate or severe dysmenorrhea and menorrhagia in 48 patients, placed Mirena for treatment, observed before Mirena treatment, 3 months after treatment , 6 months, 12 months dysmenorrhea, menstrual flow, hemoglobin, serum CA125 levels, changes in uterine volume, changes in endometrial thickness and so on. Results: Menstruation was relieved at 3 months after Mirena treatment, and the amount of menstruation was significantly reduced and the thickness of endometrium was thinner, which was significantly different from that before placement (P <0.05). Ten anemia patients were placed (P <0.05). The level of serum CA125 decreased significantly at 12 months after being placed, compared with that before placed (P <0.05) Before the difference was statistically significant (P <0.05). Uterine volume slightly reduced, but compared with before the placement were no significant difference (P> 0.05). Adverse reactions mainly showed 4 cases of vaginal bleeding, 3 cases of amenorrhea, 1 case of breast pain, 1 case of ring off, the other no adverse reactions. Conclusion: Mirena is safe and effective in the treatment of adenomyosis and has good clinical value.